A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers Full Text
Investigational New Drugs, 06/26/2012
Baker AF et al. – There was a trend for a decrease in circulating Trx–1 during the first four PX–12 treatment cycles in patients that had a Trx–1 baseline level >18ng/mL. Aggregate clinical trial results suggest that further clinical development of PX–12, as an intravenous infusion, is not feasible. However, the Trx–1 pathway remains a target of interest in patients with gastrointestinal malignancies.